Abstract
Premature menopause defined as secondary amenorrhea is common in women with kidney disease. Moreover, the aging population has resulted in increasing numbers of postmenopausal women with kidney disease. Though the pathophysiology is poorly understood, kidney transplantation and more frequent hemodialysis can restore menses and fertility, highlighting the challenges of diagnosing and managing the menopausal transition in the female population with kidney disease. Postmenopausal sex hormone levels affect renovascular physiology, but the clinical impact of menopause on kidney function is unclear. There are no guidelines on the use of postmenopausal hormone therapy specific to the population with kidney disease, and studies on the effects of postmenopausal hormone therapy in patients with kidney disease are limited to surrogate measures of cardiovascular and fracture risk. Studies examining the effects of postmenopausal hormone therapy on kidney function and albuminuria report conflicting results, which is likely reflective of differences in formulation, route of administration, accompanying progestin, and timing of initiation of treatment. Large, prospective studies examining the relationship between kidney function and menopause as well as the effects of postmenopausal hormone therapy on important clinical outcomes in women with kidney disease are warranted.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
